Zamora-Rodríguez LA, Álvarez-Félix JR, Angulo-Rojo CE, Romo-García E, Perdomo-Martinez R

Language: Spanish
References: 15
Page: 210-222
PDF size: 150.97 Kb.

ABSTRACT

Objective. To analyze the expression of micro-RNA 146a in healthy patients and in patients with dry eye to determine its relationship with this disease. Material and Methods. An observational, descriptive and cross-sectional investigation was carried out in healthy patients with dry eye from Hospital Civil de Culiacán by measuring with the OSDI test, Schirmer's test, TRPL and AML, PCR of tear and blood samples to quantify the miRNA 146a, during the period from October to December 2020. Results. A total of 40 patients were studied, 20 with dry eye disease and 20 without ocular pathology, finding an average age of 53.2 and 52.4 years old respectively, a severe classification of dry eye was found by OSDI, pathological by Schirmer´s test, and low production by TBUT an TMH in the DED group, with normal results in control patients. The expression profile of the miRNA 146a in tear with a rate of change of 1.706 (SD 1.869) in the cases and 0.4144 (SD 0.3136) in the controls (p = 0.0155); while in serum 1.798 (SD 2.159) in the cases and 0.6540 (SD 0.4447) in the controls (p= 0.2526). Conclusions. A rate of overexpression of miRNA 146a in tears was found in 14 of 20 subjects with dry eye, being 2 times more than in control patients, which a statistically significant p, which suggest a possible association with the development of dry eye disease.

REFERENCES

1. Craig JP, Nichols KK, Akpek EK, Caffery B,Dua HS, Joo CK, et al. TFOS DEWS II definitionand classification report. Ocul Surf. 2017;15(3):276-83.

2. Yasir ZH, Chauhan D, Khardekar R, SouruC, Varghese S. Prevalence and determinantsof dry eye disease among 40 yearsand older population of Riyadh, Saudi Arabia.Mid Eas Afr J Opht. 2019;26(1):27–32.

3. Tsubota K, Yokoi N, Shimazaki J, WatanabeH, Dogru M, Yamada M, et al.; Asia Dry EyeSociety. New perspectives on dry eye definitionand diagnosis: a consensus report of theAsia Dry Eye Society. Ocul Surf.2017;15(1):65–76.

4. Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, et al. TFOSDEWS II management and therapy report.Ocul Surf. 2017;15(3):575–628.

5. Obaid A, Mohammed B, Ahmedfouad S, AlotaibiA, Yousuf B, Nezar M, et al. Etiology,prevalence, risk factors, and treatment of dryeye disease. IJMDC. 2020;4(1):137-142.

6. Ambros V. The functions of animal microRNAs.Nature. 2004; 431:350-5.

7. Li L, Chen XP, Li YJ. MicroRNA􀇦146a andhuman disease. Scand J Immunol.2010;71(4):227-31.

8. Pauley KM, Satoh M, Chan AL, Bubb MR,Reeves WH, Chan EK. Upregulated miR-146a expression in peripheral blood mononuclearcells from rheumatoid arthritis patients.Arthritis Res Ther. 2008;10(4): R101.

9. Nakasa T, Miyaki S, Okubo A, Hashimoto M,Nishida K, Ochi M, et al. Expression of microRNA􀇦146 in rheumatoid arthritis synovialtissue. Arthritis Rheum. 2008;58(5):1284-92.

10. Wei Y, Li N, Zhao L, Yang C, Ma B, Li X, etal. MicroRNAs and Autoimmune-MediatedEye Diseases. Front. Cell Dev. Biol. 2020;(8):818.

11. Ellwein LB, Urato CJ. Use of eye care andassociated charges among the Medicare population:1991-1998. Arch Ophthalmol.2002;120(6):804-11.

12. Janine AS. The epidemiology of dry eye disease:report of the epidemiological subcommitteeof the international dry eye workshop.Ocul Surf. 2007;5(2):93-107.

13. Schaumberg DA, Sullivan DA, Buring JE,Dana MR. Prevalence of dry eye syndromeamong US women. Am J Ophtalmol.2003;136(2):318-26.

14. Bron AJ, Tomlinson A, Foulks GN, PeposeJS, Baudouin C, Geerling G, et al. Rethinkingdry eye disease: a perspective on clinicalimplications. Ocul Surf. 2014;12(2): S1-31.

15. Nichols KK, Foulks GN, Bron AJ, GlasgowBJ, Dogru M, Tsubota K, et al. The internationalworkshop on meibomian gland dysfunction:executive summary. Invest OphthalmolVis Sci. 2011;52(4):1922-9.